Friday, February 27, 2026

In Detail Full day, Friday, February 27, 2026, Timezone: America/Chicago

Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus

oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]

AI Summary: Generate Biomedicines priced a U.S. IPO at $16 per share, selling 25 million shares and raising about $400 million to advance AI-designed drugs — notably a less-frequent injection candidate for severe asthma. The offering renews investor appetite for AI-driven biotech and funds pivotal clinical work, while whispering about a lofty post-listing valuation.

UHS posts 11.5% operating margin in 2025 as net income jumps 30%

Andrew Cass / beckershospitalreview - King of Prussia, Pa.-based Universal Health Services recorded a net income of $1.5 billion in 2025, up from $1.1 billion in 2024, according to its Feb. 25 financial report. Eight things to know: 1. The for-profit system reported an operating income of $2 …

AI Summary: Universal Health Services reported robust 2025 financial results and outlined an optimistic 2026 outlook, driven by acute and behavioral health operations. Leadership flagged growth targets for admissions and behavioral services even as staffing and regulatory pressures persist — the usual blend of confidence and contingency planning.